logo

MYGN

Myriad Genetics·NASDAQ
--
--(--)
--
--(--)
4.03 / 10
Netural

The equity presents balanced fundamental picture (4.0/10). Strengths include Profit-MV and Cash-MV, with caution warranted for Net profit / Total profit (%) and Asset-MV. This merits prudent consideration.

Fundamental(4.03)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value0.74
Score3/3
Weight45.33%
1M Return20.82%
Inventory turnover ratio
Value6.26
Score2/3
Weight-3.34%
1M Return-2.63%
Gross profit margin (%)
Value69.92
Score2/3
Weight2.18%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight13.18%
1M Return7.79%
PB-ROE
Value-0.15
Score1/3
Weight12.17%
1M Return7.02%
Current assets turnover ratio
Value1.91
Score2/3
Weight1.54%
1M Return1.15%
Fixed assets turnover ratio
Value3.68
Score2/3
Weight0.17%
1M Return0.12%
Asset-MV
Value-0.50
Score1/3
Weight15.97%
1M Return8.74%
Cash-MV
Value-0.09
Score2/3
Weight13.20%
1M Return7.73%
Net profit / Total profit (%)
Value92.70
Score0/3
Weight-0.39%
1M Return-0.30%
Is MYGN fundamentally strong?
  • MYGN scores 4.03/10 on fundamentals and holds a Fair valuation at present. Backed by its -66.67% ROE, -48.53% net margin, -1.19 P/E ratio, 1.28 P/B ratio, and -239.84% earnings growth, these metrics solidify its Netural investment rating.